The Neurosteroid Allopregnanolone Is Reduced in Prefrontal Cortex in Alzheimer's Disease

Biological Psychiatry

Volumn 60, Issue 12, 2006, Pages 1287-1294

  Marx, Christine E ^a,e   Trost, William T ^a,e   Shampine, Lawrence J ^a,e   Stevens, Robert D ^b   Hulette, Christine M ^c,d   Steffens, David C ^a   Ervin, John F ^c,d   Butterfield, Marian I ^a,e   Blazer, Daniel G ^a   Massing, Mark W ^e   Lieberman, Jeffrey A ^f  

^a Department of Psychiatry and Behavioral Sciences ^*  (United States)

^b DUKE UNIVERSITY   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e DURHAM VA MEDICAL CENTER   (United States)

^f Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

allopregnanolone; Alzheimer's disease; dehydroepiandrosterone; neurosteroid; postmortem; prefrontal cortex

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; NEUROSTEROID; PRASTERONE; PREGNENOLONE;

ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MALE; MASS SPECTROMETRY; NEUROPATHOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEHYDROEPIANDROSTERONE; DISEASE PROGRESSION; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; PREFRONTAL CORTEX; PREGNANOLONE; PREGNENOLONE;

EID: 33751539032     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2006.06.017     Document Type: Article

References (94)

1. Ahmad I., Lope-Piedrafita S., Bi X., Hicks C., Yao Y., Yu C., et al. Allopregnanolone treatment, both as a single injection or repetitively, delays demyelination and enhances survival of Niemann-Pick C mice. J Neurosci Res 82 (2005) 811-821
2. Akwa Y., Ladurelle N., Covey D.F., and Baulieu E.E. The synthetic enantiomer of pregnenolone sulfate is very active on memory in rats and mice, even more so than its physiological neurosteroid counterpart: Distinct mechanisms?. Proc Natl Acad Sci U S A 98 (2001) 14033-14037
3. Alhaj H.A., Massey A.E., and McAllister-Williams R.H. Effects of DHEA administration on episodic memory, cortisol and mood in healthy young men: a double-blind, placebo-controlled study. Psychopharmacology (Berl) (2005) 1-11
4. Alomary A.A., Fitzgerald R.L., and Purdy R.H. Neurosteroid analysis. Int Rev Neurobiol 46 (2001) 97-115
5. Azcoitia I., Leonelli E., Magnaghi V., Veiga S., Garcia-Segura L.M., and Melcangi R.C. Progesterone and its derivatives dihydroprogesterone and tetrahydroprogesterone reduce myelin fiber morphological abnormalities and myelin fiber loss in the sciatic nerve of aged rats. Neurobiol Aging 24 (2003) 53-860
6. Barbaccia M.L., Affricano D., Purdy R.H., Maciocco E., Spiga F., and Biggio G. Clozapine, but not haloperidol, increases brain concentrations of neuroactive steroids in the rat. Neuropsychopharmacology 25 (2001) 89-497
7. Bartzokis G. Age-related myelin breakdown: A developmental model of cognitive decline and Alzheimer's disease. Neurobiol Aging 25 (2004) 5-18 author reply 49-62
8. Bastianetto S., Ramassamy C., Poirier J., and Quirion R. Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage. Brain Res Mol Brain Res 66 (1999) 35-41
9. Belelli D., and Lambert J.J. Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat Rev Neurosci 6 (2005) 565-575
10. Benes F.M. A disturbance of late myelination as a trigger for Alzheimer's disease. Neurobiol Aging 25 (2004) 41-43
11. Bergeron R., de Montigny C., and Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. J Neurosci 16 (1996) 1193-1202
12. Bernardi F., Lanzone A., Cento R.M., Spada R.S., Pezzani I., Genazzani A.D., et al. Allopregnanolone and dehydroepiandrosterone response to corticotropin-releasing factor in patients suffering from Alzheimer's disease and vascular dementia. Eur J Endocrinol 142 (2000) 466-471
13. Bixo M., Andersson A., Winblad B., Purdy R.H., and Backstrom T. Progesterone, 5alpha-pregnane-3,20-dione and 3alpha-hydroxy-5alpha-pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res 764 (1997) 173-178
14. Boccuzzi G., Aragno M., Seccia M., Brignardello E., Tamagno E., Albano E., et al. Protective effect of dehydroepiandrosterone against copper-induced lipid peroxidation in the rat. Free Radic Biol Med 22 (1997) 1289-1294
15. Braak H., and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82 (1991) 239-259
16. Brown R.C., Cascio C., and Papadopoulos V. Pathways of neurosteroid biosynthesis in cell lines from human brain: Regulation of dehydroepiandrosterone formation by oxidative stress and beta-amyloid peptide. J Neurochem 74 (2000) 847-859
17. Brown R.C., Han Z., Cascio C., and Papadopoulos V. Oxidative stress-mediated DHEA formation in Alzheimer's disease pathology. Neurobiol Aging 24 (2003) 57-65
18. Cardounel A., Regelson W., and Kalimi M. Dehydroepiandrosterone protects hippocampal neurons against neurotoxin-induced cell death: Mechanism of action. Proc Soc Exp Biol Med 222 (1999) 145-149
19. Ciriza I., Azcoitia I., and Garcia-Segura L.M. Reduced progesterone metabolites protect rat hippocampal neurones from kainic acid excitotoxicity in vivo. J Neuroendocrinol 16 (2004) 58-63
20. Compagnone N.A., and Mellon S.H. Dehydroepiandrosterone: A potential signalling molecule for neocortical organization during development. Proc Natl Acad Sci USA 95 (1998) 4678-4683
21. Corpechot C., Robel P., Axelson M., Sjovall J., and Baulieu E.E. Characterization and measurement of dehydroepiandrosterone sulfate in rat brain. Proc Natl Acad Sci USA 78 (1981) 4704-4707
22. Counterman A.E., D'Onofrio T.G., Andrews A.M., and Weiss P.S. From the Cover: A physical model of axonal damage due to oxidative stress. Proc Natl Acad Sci USA 103 (2006) 5262-5266
23. Cutler R.G., Kelly J., Storie K., Pedersen W.A., Tammara A., Hatanpaa K., et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci USA 101 (2004) 2070-2075
24. Debonnel G., Bergeron R., Monnet F.P., and De Montigny C. Differential effects of sigma ligands on the N-methyl-D-aspartate response in the CA1 and CA3 regions of the dorsal hippocampus: Effect of mossy fiber lesioning. Neuroscience 71 (1996) 977-987
25. Djebaili M., Guo Q., Pettus E.H., Hoffman S.W., and Stein D.G. The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. J Neurotrauma 22 (2005) 106-118
26. Djebaili M., Hoffman S.W., and Stein D.G. Allopregnanolone and progesterone decrease cell death and cognitive deficits after a contusion of the rat pre-frontal cortex. Neuroscience 123 (2004) 349-359
27. Dong E., Matsumoto K., Uzunova V., Sugaya I., Takahata H., Nomura H., et al. Brain 5alpha-dihydroprogesterone and allopregnanolone synthesis in a mouse model of protracted social isolation. Proc Natl Acad Sci USA 98 (2001) 2849-2854
28. Ebner M.J., Corol D.I., Havlikova H., Honour J.W., and Fry J.P. Identification of neuroactive steroids and their precursors and metabolites in adult male rat brain. Endocrinology 147 (2006) 179-190
29. Flood J.F., Morley J.E., and Roberts E. Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it. Proc Natl Acad Sci USA 89 (1992) 1567-1571
30. Flood J.F., Morley J.E., and Roberts E. Pregnenolone sulfate enhances post-training memory processes when injected in very low doses into limbic system structures: The amygdala is by far the most sensitive. Proc Natl Acad Sci USA 92 (1995) 10806-10810
31. Francis P.T. The interplay of neurotransmitters in Alzheimer's disease. CNS Spectr 10 Suppl 18 (2005) 6-9
32. Genazzani A.R., Petraglia F., Bernardi F., Casarosa E., Salvestroni C., Tonetti A., et al. Circulating levels of allopregnanolone in humans: Gender, age, and endocrine influences. J Clin Endocrinol Metab 83 (1998) 2099-2103
33. Ghoumari A.M., Ibanez C., El-Etr M., Leclerc P., Eychenne B., O'Malley B.W., et al. Progesterone and its metabolites increase myelin basic protein expression in organotypic slice cultures of rat cerebellum. J Neurochem 86 (2003) 848-859
34. Girdler S.S., Straneva P.A., Light K.C., Pedersen C.A., and Morrow A.L. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry 49 (2001) 788-797
35. Glantz L.A., and Lewis D.A. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch of Gen Psych 57 (2000) 65-73
36. Griffin L.D., Gong W., Verot L., and Mellon S.H. Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat Med 10 (2004) 704-711
37. Griffin L.D., and Mellon S.H. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci USA 96 (1999) 13512-13517
38. Griffin L.D., and Mellon S.H. Biosynthesis of the neurosteroid 3 alpha-hydroxy-4-pregnen-20-one (3 alpha hp), a specific inhibitor of FSH release. Endocrinology 142 (2001) 4617-4622
39. He J., Hoffman S.W., and Stein D.G. Allopregnanolone, a progesterone metabolite, enhances behavioral recovery and decreases neuronal loss after traumatic brain injury. Restor Neurol Neurosci 22 (2004) 19-31
40. Higashi T., Daifu Y., Ikeshima T., Yagi T., and Shimada K. Studies on neurosteroids XV. Development of enzyme-linked immunosorbent assay for examining whether pregnenolone sulfate is a veritable neurosteroid. J Pharm Biomed Anal 30 (2003) 1907-1917
41. Hulette C.M., Welsh-Bohmer K.A., Crain B., Szymanski M.H., Sinclaire N.O., and Roses A.D. Rapid brain autopsy. The Joseph and Kathleen Bryan Alzheimer's Disease Research Center experience. Arch Pathol Lab Med 121 (1997) 615-618
42. Hynd M.R., Scott H.L., and Dodd P.R. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 45 (2004) 583-595
43. Jellinger K.A. Head injury and dementia. Curr Opin Neurol 17 (2004) 719-723
44. Jin L.W., Shie F.S., Maezawa I., Vincent I., and Bird T. Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am J Pathol 164 (2004) 975-985
45. Karishma K.K., and Herbert J. Dehydroepiandrosterone (DHEA) stimulates neurogenesis in the hippocampus of the rat, promotes survival of newly formed neurons and prevents corticosterone-induced suppression. Eur J Neurosci 16 (2002) 445-453
46. Kim S.B., Hill M., Kwak Y.T., Hampl R., Jo D.H., and Morfin R. Neurosteroids: Cerebrospinal fluid levels for Alzheimer's disease and vascular dementia diagnostics. J Clin Endocrinol Metab 88 (2003) 5199-5206
47. Kimonides V.G., Khatibi N.H., Svendsen C.N., Sofroniew M.V., and Herbert J. Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS) protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. Proc Natl Acad Sci USA 95 (1998) 1852-1857
48. Kimonides V.G., Spillantini M.G., Sofroniew M.V., Fawcett J.W., and Herbert J. Dehydroepiandrosterone antagonizes the neurotoxic effects of corticosterone and translocation of stress-activated protein kinase 3 in hippocampal primary cultures. Neuroscience 89 (1999) 429-436
49. Korolainen M.A., Goldsteins G., Nyman T.A., Alafuzoff I., Koistinaho J., and Pirttila T. Oxidative modification of proteins in the frontal cortex of Alzheimer's disease brain. Neurobiol Aging 27 (2006) 42-53
50. Liere P., Pianos A., Eychenne B., Cambourg A., Liu S., Griffiths W., et al. Novel lipoidal derivatives of pregnenolone and dehydroepiandrosterone and absence of their sulfated counterparts in rodent brain. J Lipid Res 45 (2004) 2287-2302
51. Lipton S.A. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: Low-affinity, uncompetitive antagonism. Curr Alzheimer Res 2 (2005) 155-165
52. Liu S., Sjovall J., and Griffiths W.J. Neurosteroids in rat brain: Extraction, isolation, and analysis by nanoscale liquid chromatography-electrospray mass spectrometry. Anal Chem 75 (2003) 5835-5846
53. Lockhart E.M., Warner D.S., Pearlstein R.D., Penning D.H., Mehrabani S., and Boustany R.M. Allopregnanolone attenuates N-methyl-D-aspartate-induced excitotoxicity and apoptosis in the human NT2 cell line in culture. Neurosci Lett 328 (2002) 33-36
54. Majewska M.D., Harrison N.L., Schwartz R.D., Barker J.L., and Paul S.M. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 232 (1986) 1004-1007
55. Mariani E., Polidori M.C., Cherubini A., and Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Analyt Technol Biomed Life Sci 827 (2005) 65-75
56. Marx C.E., Duncan G.E., Gilmore J.H., Lieberman J.A., and Morrow A.L. Olanzapine increases allopregnanolone in the rat cerebral cortex. Biol Psychiatry 47 (2000) 1000-1004
57. Marx CE, Shampine LJ, Khisti RT, Trost WT, Bradford DW, Grobin AC, et al (in press): Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone, and peripheral deoxycorticosterone: Implications for therapeutic actions. Pharmacol, Biochem, and Behav.
58. Marx C.E., Stevens R.D., Shampine L.J., Uzunova V., Trost W.T., Butterfield M.I., et al. Neuroactive steroids are altered in schizophrenia and bipolar disorder: Relevance to pathophysiology and therapeutics. Neuropsychopharmacology 31 (2006) 1249-1263
59. Marx C.E., VanDoren M.J., Duncan G.E., Lieberman J.A., and Morrow A.L. Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology 28 (2003) 1-13
60. Maurice T., Su T.P., and Privat A. Sigma1 (sigma 1) receptor agonists and neurosteroids attenuate B25-35-amyloid peptide-induced amnesia in mice through a common mechanism. Neuroscience 83 (1998) 413-428
61. Mellon S.H., and Griffin L.D. Synthesis, regulation, and function of neurosteroids. Endocr Res 28 (2002) 463
62. Meunier J., and Maurice T. Beneficial effects of the sigma1 receptor agonists igmesine and dehydroepiandrosterone against learning impairments in rats prenatally exposed to cocaine. Neurotoxicol Teratol 26 (2004) 783-797
63. Morrow A.L., Pace J.R., Purdy R.H., and Paul S.M. Characterization of steroid interactions with gamma-aminobutyric acid receptor-gated chloride ion channels: Evidence for multiple steroid recognition sites. Mol Pharmacol 37 (1990) 263-270
64. Morrow A.L., Suzdak P.D., and Paul S.M. Steroid hormone metabolites potentiate GABA receptor-mediated chloride ion flux with nanomolar potency. Eur J Pharmacol 142 (1987) 483-485
65. Nemetz P.N., Leibson C., Naessens J.M., Beard M., Kokmen E., Annegers J.F., et al. Traumatic brain injury and time to onset of Alzheimer's disease: A population-based study. Am J Epidemiol 149 (1999) 32-40
66. Papassotiropoulos A., Wollmer M.A., Tsolaki M., Brunner F., Molyva D., Lutjohann D., et al. A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. J Clin Psychiatry 66 (2005) 940-947
67. Paul S.M., and Purdy R.H. Neuroactive steroids. Faseb J 6 (1992) 2311-2322
68. Pinna G., Dong E., Matsumoto K., Costa E., and Guidotti A. In socially isolated mice, the reversal of brain allopregnanolone down-regulation mediates the anti-aggressive action of fluoxetine. PNAS 100 (2003) 2035-2040
69. Prabakaran S., Swatton J.E., Ryan M.M., Huffaker S.J., Huang J.T.-J., Griffin J.L., et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Molec Psychiatry 9 (2004) 684-697
70. Puglielli L., Tanzi R.E., and Kovacs D.M. Alzheimer's disease: The cholesterol connection. Nat Neurosci 6 (2003) 345-351
71. Purdy R., Fitzgerald R., Alomary A., and Parsons L. Practical neurochemistry: Methods. In: Baker G. (Ed). Handbook of Neurochemistry and Molecular Neurobiology. 3rd ed. vol 18. (2006), Springer, New York 1-15
72. Purdy R.H., Morrow A.L., Blinn J.R., and Paul S.M. Synthesis, metabolism, and pharmacological activity of 3 alpha-hydroxy steroids which potentiate GABA-receptor-mediated chloride ion uptake in rat cerebral cortical synaptoneurosomes. J Med Chem 33 (1990) 1572-1581
73. Ramassamy C., Averill D., Beffert U., Bastianetto S., Theroux L., Lussier-Cacan S., et al. Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radic Biol Med 27 (1999) 544-553
74. Roberts E., Bologa L., Flood J.F., and Smith G.E. Effects of dehydroepiandrosterone and its sulfate on brain tissue in culture and on memory in mice. Brain Res 406 (1987) 357-362
75. Rupprecht R., and Holsboer F. Neuroactive steroids: Mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 22 (1999) 410-416
76. Shobab L.A., Hsiung G.Y., and Feldman H.H. Cholesterol in Alzheimer's disease. Lancet Neurol 4 (2005) 841-852
77. Shu H.J., Eisenman L.N., Jinadasa D., Covey D.F., Zorumski C.F., and Mennerick S. Slow actions of neuroactive steroids at GABAA receptors. J Neurosci 24 (2004) 6667-6675
78. Smith C.D., Wekstein D.R., Markesbery W.R., and Frye C.A. 3alpha,5alpha-THP: a potential plasma neurosteroid biomarker in Alzheimer's disease and perhaps non-Alzheimer's dementia. Psychopharmacology (Berl) (2005) 1-5
79. Suzuki M., Wright L.S., Marwah P., Lardy H.A., and Svendsen C.N. Mitotic and neurogenic effects of dehydroepiandrosterone (DHEA) on human neural stem cell cultures derived from the fetal cortex. Proc Natl Acad Sci USA 101 (2004) 3202-3207
80. Torrey E.F., Barci B.M., Webster M.J., Bartko J.J., Meador-Woodruff J.H., and Knable M.B. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol Psychiatry 57 (2005) 252-260
81. Treiber-Held S., Distl R., Meske V., Albert F., and Ohm T.G. Spatial and temporal distribution of intracellular free cholesterol in brains of a Niemann-Pick type C mouse model showing hyperphosphorylated tau protein. Implications for Alzheimer's disease. J Pathol 200 (2003) 95-103
82. Tunez I., Munoz M.C., and Montilla P. Treatment with dehydroepiandrosterone prevents oxidative stress induced by 3-nitropropionic acid in synaptosomes. Pharmacology 74 (2005) 113-118
83. Uzunov D.P., Cooper T.B., Costa E., and Guidotti A. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc Natl Acad Sci USA 93 (1996) 12599-12604
84. Uzunova V., Sheline Y., Davis J.M., Rasmusson A., Uzunov D.P., Costa E., et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 95 (1998) 3239-3244
85. Vallee M., Mayo W., Darnaudery M., Corpechot C., Young J., Koehl M., et al. Neurosteroids: Deficient cognitive performance in aged rats depends on low pregnenolone sulfate levels in the hippocampus. Proc Natl Acad Sci USA 94 (1997) 14865-14870
86. Vallee M., Purdy R.H., Mayo W., Koob G.F., and Le Moal M. Neuroactive steroids: New biomarkers of cognitive aging. J Steroid Biochem Mol Biol 85 (2003) 329-335
87. Vance J.E., Hayashi H., and Karten B. Cholesterol homeostasis in neurons and glial cells. Semin Cell Dev Biol 16 (2005) 193-212
88. Wang J.M., Johnston P.B., Ball B.G., and Brinton R.D. The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. J Neurosci 25 (2005) 4706-4718
89. Weill-Engerer S., David J.P., Sazdovitch V., Liere P., Eychenne B., Pianos A., et al. Neurosteroid quantification in human brain regions: Comparison between Alzheimer's and nondemented patients. J Clin Endocrinol Metab 87 (2002) 5138-5143
90. Wenk G. Neuropathologic changes in Alzheimer's disease: Potential targets for treatment. J Clin Psychiatry 67 Suppl 3 (2006) 3-7
91. Wolf O.T., and Kirschbaum C. Actions of dehydroepiandrosterone and its sulfate in the central nervous system: Effects on cognition and emotion in animals and humans. Brain Res Brain Res Rev 30 (1999) 264-288
92. Wolkowitz O.M., Kramer J.H., Reus V.I., Costa M.M., Yaffe K., Walton P., et al. DHEA treatment of Alzheimer's disease: A randomized, double-blind, placebo-controlled study. Neurology 60 (2003) 1071-1076
93. Wolozin B. Cholesterol and the biology of Alzheimer's disease. Neuron 41 (2004) 7-10
94. Yu W., Ko M., Yanagisawa K., and Michikawa M. Neurodegeneration in heterozygous Niemann-Pick type C1 (NPC1) mouse: Implication of heterozygous NPC1 mutations being a risk for tauopathy. J Biol Chem 280 (2005) 27296-27302